Compare FND & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | PCVX |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 8.7B |
| IPO Year | 2014 | 2020 |
| Metric | FND | PCVX |
|---|---|---|
| Price | $53.22 | $62.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $77.25 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.05 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $4,684,088,000.00 | N/A |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $7.78 | N/A |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $46.47 | $28.09 |
| 52 Week High | $92.41 | $65.00 |
| Indicator | FND | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 65.54 |
| Support Level | $46.47 | $42.30 |
| Resistance Level | $64.23 | $65.00 |
| Average True Range (ATR) | 2.57 | 2.28 |
| MACD | 0.81 | 0.62 |
| Stochastic Oscillator | 87.19 | 95.44 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site. The company segments include retail segment and others.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.